Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba J L, Sangro B
Eur J Gynaecol Oncol. 1987;8(2):98-102.
Twenty-six patients suffering from disseminated epithelial ovarian cancer (FIGO stages III and IV) under treatment with Cisplatin (80-100 mg/m2 in 8 hours) in combination on the same day with Cyclophosphamide (500 mg/m2 IV) and Adriamycin (50 mg/m2), a severely emetogenic regimen, entered a randomized, double-blind, cross-over trial comparing the antiemetic activity of high-dose IV Metoclopramide (1 mg/kg/dose X 5 doses) with that of a combination of Metoclopramide (same schedule) plus Nortriptyline (50 mg PO X 2 doses) plus Thiethylperazine (10 mg IV X 3 doses). The antiemetic combination was designed in an attempt to act simultaneously on gastrointestinal motility and neuroreceptors at the central emetic pathways (dopamine D-2, histamine H-1 and muscarinic cholinergic). This combination significantly reduced the emesis due to chemotherapy when compared with Metoclopramide alone and was also preferred by a significant number of patients after passing through both the antiemetic arms being compared.
26例患有播散性上皮性卵巢癌（国际妇产科联盟分期III期和IV期）的患者，接受顺铂（80 - 100mg/m²，8小时输注）联合环磷酰胺（500mg/m²静脉注射）和阿霉素（50mg/m²）治疗，这是一种强致吐性方案，这些患者进入了一项随机、双盲、交叉试验，比较大剂量静脉注射甲氧氯普胺（1mg/kg/剂量×5剂）与甲氧氯普胺（相同给药方案）加去甲替林（50mg口服×2剂）加硫乙拉嗪（10mg静脉注射×3剂）联合用药的止吐活性。该止吐联合用药旨在同时作用于胃肠道蠕动以及中枢催吐途径的神经受体（多巴胺D - 2、组胺H - 1和毒蕈碱胆碱能受体）。与单独使用甲氧氯普胺相比，这种联合用药显著减少了化疗引起的呕吐，并且在经过两种被比较的止吐方案治疗后，也有相当数量的患者更倾向于这种联合用药。
